Thermo Fisher Scientific SPG11 Polyclonal Antibody

Applications

Immunohistochemistry (Paraffin) (IHC (P))

• Tested Dilution: 1:500–1:1,000

Immunocytochemistry (ICC/IF)

• Tested Dilution: 0.25–2 µg/mL

Product Specifications

Product Specific Information

Immunogen sequence:
IKFPWKLTDA IDEYDVHENV PKVKESNIWK KLSFEEVIAS AILNNKIPEA QTFFRIDSHS AQKLEELIGI GLNLVFDNLK KNNIKEASEL LKNMGFDVKG QLLKICFYTT

• Highest antigen sequence identity to orthologs:
  • Mouse: 73%
  • Rat: 68%

Target Information

Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders. Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a frequent form of complicated hereditary spastic paraplegia (cHSP). Mutations in the SPG11 gene encoding the spatacsin protein are a major cause of HSP-TCC.
Spatacsin is a potential transmembrane protein phosphorylated upon DNA damage and expressed throughout the brain, especially in the cerebellum. SPG11 mutations are more common in familial cHSP without TCC. Kjellin syndrome is associated with SPG11 and SPG15 mutations. Recent studies suggest SPG11 may be linked to juvenile Parkinsonism.

For Research Use Only.
Not for use in diagnostic procedures. Not for resale without express authorization.